Phenylketonuria (PKU) Market Report 2026

Phenylketonuria (PKU) Market Overview

• Phenylketonuria (PKU) market size has reached to $0.93 billion in 2025 • Expected to grow to $1.4 billion in 2030 at a compound annual growth rate (CAGR) of 8.5% • Growth Driver: Increasing Cases Of Genetic Disorders Driving The Growth Of The Market • Market Trend: Emerging Oral Therapies for the Management of Phenylketonuria (PKU) • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Phenylketonuria (PKU) Market?

Phenylketonuria (PKU) is a rare inherited metabolic disorder in which the body cannot break down an amino acid called phenylalanine (Phe) found in many protein-containing foods. This inability is due to a deficiency or malfunction of the phenylalanine hydroxylase (PAH) enzyme, which normally converts phenylalanine into another amino acid called tyrosine. The main types of phenylketonuria (PKU) in the phenylketonuria market are hyperphenylalaninemia (HPA), mild phenylketonuria (PKU), moderate and variant PKU, and classic phenylketonuria (PKU). Hyperphenylalaninemia (HPA) is a genetic metabolic disorder caused by a deficiency of phenylalanine hydroxylase, leading to elevated blood phenylalanine levels. Treatment types include enzyme replacement therapy, gene therapy, medication, and dietary therapy. Diagnosis methods include genetic testing, biochemical testing, and newborn screening. The key end-users of PKU treatments and diagnostics are specialty clinics, research institutes, home healthcare providers, and hospitals.

What Is The Phenylketonuria (PKU) Market Growth Forecast?

The phenylketonuria (pku) market size is expected to see strong growth in the next few years. It will grow to $1.4 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to growing pipeline of gene therapies, increasing adoption of precision medicine approaches, rising investments in rare disease research, expansion of home-based management solutions, growing demand for long-term disease control therapies. Major trends in the forecast period include increasing adoption of enzyme replacement therapies, rising focus on gene therapy development, growing demand for personalized dietary management solutions, expansion of newborn screening programs, enhanced integration of digital patient monitoring tools.

Global Phenylketonuria (PKU) Market Segmentation

1) By Type: Hyperphenylalaninemia, Mild Phenylketonuria (PKU), Moderate And Variant, Classic Phenylketonuria (PKU) 2) By Treatment Type: Enzyme Replacement Therapy, Gene Therapy, Medication, Dietary Therapy 3) By Diagnosis: Genetic Testing, Biochemical Testing, Newborn Screening 4) By End-User: Specialty Clinics, Research Institutes, Home Healthcare, Hospitals Subsegments: 1) By Hyperphenylalaninemia: Mild Hyperphenylalaninemia, Moderate Hyperphenylalaninemia, Severe Hyperphenylalaninemia 2) By Mild Phenylketonuria (PKU): Mild PKU with dietary management, Mild PKU with enzyme supplementation 3) By Moderate And Variant: Moderate PKU with medication, Variant PKU with treatment variations 4) By Classic Phenylketonuria (PKU): Classic PKU with strict dietary management, Classic PKU with enzyme replacement therapy

What Is The Driver Of The Phenylketonuria (PKU) Market?

The increasing cases of genetic disorders are expected to propel the growth of the phenylketonuria (PKU) market going forward. Genetic disorders refer to medical conditions caused by abnormalities in an individual's DNA, such as mutations, deletions, or duplications of genes or chromosomes. The increasing cases of genetic disorders are attributed to factors such as rising maternal age, environmental influences, advancements in diagnostic technologies, and higher awareness, leading to improved detection rates. Phenylketonuria contributes to understanding genetic disorders by demonstrating how inherited enzyme deficiencies can lead to severe metabolic complications. For instance, in March 2024, Gene People, a UK-based registered charity, stated that genetic conditions affect an estimated 1 in 25 children, impacting over 2.4 million children and adults in the UK. Additionally, around 30,000 newborns and children in the UK are diagnosed with a genetic condition each year. Therefore, the increasing cases of genetic disorders are driving the growth of the phenylketonuria (PKU) industry.

Key Players In The Global Phenylketonuria (PKU) Market

Major companies operating in the phenylketonuria (pku) market are Abbott Laboratories, Merck KGaA, Agios Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., PTC Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Nutricia International Private Limited, Codexis Inc., Eton Pharmaceuticals Inc., Vitaflo International Ltd., American Gene Technologies International Inc., Cambrooke Therapeutics Inc., Generation Bio Co., Mead Johnson & Company LLC, Synlogic Inc., Homology Medicines Inc., Aeglea BioTherapeutics Inc., MetaX Biosciences Ltd., SOM Biotech SL, Applied Molecular Transport Inc., Codexis Genomics, Bluebird Bio Inc., Alnylam Pharmaceuticals Inc.

Global Phenylketonuria (PKU) Market Trends and Insights

Major companies operating in the phenylketonuria (PKU) market are focusing on the development of innovative products such as oral therapy, which allows for reduction of blood phenylalanine (Phe) levels, helping prevent the toxic buildup that causes complications in phenylketonuria (PKU). Oral therapy is a type of medical treatment that is taken by mouth, and medicine is swallowed and absorbed through the digestive system. For instance, in July 2025, PTC Therapeutics, a US-based biopharmaceutical company, received Food and Drug Administration (FDA) approval for Sephience (sepiapterin), an oral therapy for children and adults with sepiapterin-responsive PKU/hyperphenylalaninemia. The treatment enhances phenylalanine metabolism by boosting the activity of the deficient PAH enzyme through increased tetrahydrobiopterin (BH₄) levels, helping to reduce blood phenylalanine concentrations. Additionally, Sephience is designed to be used alongside a phenylalanine-restricted diet, providing a convenient and targeted option for long-term management of PKU in responders.

What Are Latest Mergers And Acquisitions In The Phenylketonuria (PKU) Market?

In August 2024, Otsuka Holdings Co. Ltd., a Japan-based pharmaceutical company, acquired Jnana Therapeutics Inc. for approximately $1.1 billion. With this acquisition, Otsuka Pharmaceutical gains an oral drug, JNT-517, for treating the rare genetic disorder phenylketonuria (PKU) and enhances its pipeline of innovative therapies for autoimmune diseases. Jnana Therapeutics Inc. is a US-based biotechnology company specializing in treating phenylketonuria (PKU).

Regional Outlook

North America was the largest region in the phenylketonuria (PKU) market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Phenylketonuria (PKU) Market?

The phenylketonuria (PKU) market consists of revenues earned by entities by provide services such as enzyme therapy, screening tests, PKU tests, and PKU formula. The market value includes the value of related goods sold by the service provider or included within the service offering. The phenylketonuria (PKU) market also includes sales of sapropterin (Kuvan), pegvaliase-pqpz (Palynziq) and dietary supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Phenylketonuria (PKU) Market Report 2026?

The phenylketonuria (pku) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the phenylketonuria (pku) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.